Inventiva: Nine Months of Runway, One Quarter of Truth
Ahead of a phase III MASH readout that decides the company, Inventiva quietly moved its map toward the sickest livers — and still can't retire the weight-gain question.
IVA.PA · Earnings Call · 2026-09-28
Inventiva: Nine Months of Runway, One Quarter of Truth
Inventiva's first-half 2026 call is the sound of a small biotech holding its breath. There is no revenue to parse, no guidance grid to argue over — just a €233.9 million bank balance, a fully recruited phase III trial, and a binary event sitting roughly one quarter away. The whole investment case now compresses into a single number due in Q4 2026.The Company Is Now A Single Event
For two years the NATiV3 question was “will they finish enrolling?” That is now settled. CEO Andrew Obenshain opened by calling the half “a defining period for Inventiva” — Andrew Obenshain, CEO or Senior Executive · 2026-09-28, and the operational proof is stark: “Earlier this month, the last patient completed their final 72-week visit.” — Andrew Obenshain, CEO or Senior Executive · 2026-09-28 The main cohort stands at 1,009 biopsy-confirmed F2/F3 patients; an exploratory cohort of 410 sits alongside it. The trial has become a data-processing exercise. What actually changed on the balance sheet is more consequential than the clinical calendar. In June the company tore up its old capital structure: it bought back roughly 60% of its EIB warrants, repaid the EIB loans, and raised fresh debt and equity. CFO Axel-Sven Malkomes — who twice lost his script mid-call, forcing Obenshain to improvise the numbers — reported “EUR 233.9 million of combined cash equivalents, and short-term deposits” — Andrew Obenshain, CEO or Senior Executive · 2026-09-28. Runway now runs to the end of Q2 2027, past the readout and a potential NDA filing, and could stretch to the start of Q1 2028 if warrant and debt tranches convert on positive data. The tell here is what dropped out of the top themes. Cash runway was a perennial top-ranked concern for Inventiva across 2025 and early 2026; this quarter it barely features, because the June refinancing muted it. When a biotech stops leading with financing anxiety, it is usually because it has bought itself exactly one shot at the data.The New Map: cACLD and Portal Hypertension
The genuinely new theme on this call is a geographic expansion of the disease — not the market, but the liver. For quarters, management has framed lanifibranor around F2/F3 non-cirrhotic unmet need. On Monday, Chief Medical Officer Jason Campagna sketched a next chapter in advanced disease:The vocabulary is fresh: cACLD, portal hypertension, and a confirmatory outcome trial aimed at clinically significant portal hypertension. Campagna argued the same PPAR isoforms that drive histologic benefit also act on the vascular biology behind portal pressure — a mechanistic bridge, and the rationale for the outcomes study the FDA will want underway at filing. He pointed to 75–100 cirrhotic patients already exposed in the exploratory cohort, plus Child-Pugh A/B/C hepatic-impairment data, as the groundwork. This is Inventiva reaching past a crowded non-cirrhotic fight into a population with no approved therapy. It is smart positioning, but it is also a second act announced before the first act has opened.That's worth pausing on because everything I've described targets the core pathophysiology of MASH. That same pathophysiology also underlies compensated advanced chronic liver disease, or cACLD, due to MASH... This subgroup of patients has no approved disease-modifying therapy.
The Weight-Gain Question That Refuses To Retire
If cACLD is new, the Q&A was almost entirely old. Analyst after analyst pressed on weight gain and edema — the same on-target PPAR-gamma effects that dominated the March 2026 call, when Michael Yee asked whether the weight gain plateaus and “if the weight gain is due to fluid is there any concerns about a cardiac imbalance” — Jason Campagna, Chief Medical Officer · 2026-03-31. Nothing has resolved that debate; the data still isn't unblinded. What is new is the granularity of the defense. Campagna now cites NATIVE IIb numbers: edema prevalence of 7–10% unadjusted, with just ~2% drug-related, against 20–25% for pioglitazone, and argues “the question you're really asking is, if we added an 18% one-stage improvement of fibrosis or more to that profile, would people use more or less of it?” — Jason Campagna, Medical or Clinical Development Executive · 2026-09-28 The comparison to pioglitazone's millions of annual scripts is a recurring rhetorical crutch — it appeared in prior calls too. The GLP 1 thread got a subtle refresh: management now stresses that the ~9% of patients who dropped in on GLP-1s did so at non-MASH (lower) doses, so histology should be unaffected, with sensitivity analyses pre-specified but unpowered. That is a quiet concession that the trial cannot prove an incremental GLP-1 benefit — only that it isn't contaminated.The Silence That Matters Most
Two omissions define this report. First, Obenshain flatly declined to preview the readout: “We are not guiding on the top-line data right now.” — Andrew Obenshain, CEO or Senior Executive · 2026-09-28 That is disciplined, but it also leaves 18 months of investor speculation circling the same composite endpoint. The bar was set long ago — in March, Obenshain said that replicating phase II's “18% effect on a fibrosis” — Andrew Obenshain, Chief Executive Officer · 2026-03-31 would mean “we have an excellent drug” — Andrew Obenshain, Chief Executive Officer · 2026-03-31. That 18% is still the number to beat. Second, the addressable-patient tally moved in the wrong direction. Obenshain acknowledged that Inventiva's 374,000 diagnosed F2/F3 patients sits below a competitor's 460,000, and conceded:A year ago the company cited roughly 375,000 as well — so the figure hasn't grown in management's own framing, even as it insists fibrosis improvement plus HbA1c lowering is a differentiated package for the diabetic F3 segment.The 374,000 is certainly on the low end of that.